Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat bladder cancer: experimental drug combo enters human trials

NCT ID NCT05562830

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called zilovertamab vedotin, alone or with the immunotherapy pembrolizumab, in 48 people with advanced bladder cancer that no longer responds to standard PD-1/L1 inhibitors. The study aims to see if the treatment is safe and can shrink tumors. It is part of a larger platform trial that can add new treatments as they become available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zilovertamab vedotin (a drug that targets cancer cells) with or without pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with advanced bladder cancer that no longer responds to standard immunotherapy.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply broadly. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Anschutz Cancer Pavilion ( Site 1017)

    COMPLETED

    Aurora, Colorado, 80045, United States

  • Asan Medical Center ( Site 1901)

    RECRUITING

    Seoul, 05505, South Korea

  • Bradford Hill ( Site 1155)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Cleveland Clinic-Taussig Cancer Center ( Site 1036)

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • FALP-UIDO ( Site 1151)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1408)

    RECRUITING

    Milan, Lombardy, 20133, Italy

  • Hospital Clinico San Carlos ( Site 1765)

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Universitari Vall d'Hebron ( Site 1767)

    RECRUITING

    Barcelona, Catalonia, 08035, Spain

  • Huntsman Cancer Institute ( Site 1041)

    RECRUITING

    Salt Lake City, Utah, 84112-5500, United States

  • Indiana University Melvin and Bren Simon Cancer Center ( Site 1011)

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1406)

    RECRUITING

    Naples, 80131, Italy

  • Memorial Sloan Kettering Cancer Center ( Site 1031)

    RECRUITING

    New York, New York, 10065, United States

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1302)

    RECRUITING

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Princess Margaret Cancer Centre ( Site 1106)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1201)

    RECRUITING

    London, London, City of, SW3 6JJ, United Kingdom

  • Rabin Medical Center-Oncology ( Site 1504)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus-Oncology ( Site 1501)

    RECRUITING

    Haifa, 3109601, Israel

  • Rigshospitalet-Dept. of Oncology ( Site 1701)

    RECRUITING

    Copenhagen, Capital Region, 2100, Denmark

  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952)

    COMPLETED

    Brisbane, Queensland, 4029, Australia

  • Samsung Medical Center ( Site 1902)

    RECRUITING

    Seoul, 06351, South Korea

  • Severance Hospital, Yonsei University Health System ( Site 1903)

    RECRUITING

    Seoul, 03722, South Korea

  • Sheba Medical Center-ONCOLOGY ( Site 1503)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Siteman Cancer Center ( Site 1038)

    RECRUITING

    St Louis, Missouri, 63108, United States

  • St Bartholomew's Hospital ( Site 1206)

    RECRUITING

    London, London, City of, EC1A 7BE, United Kingdom

  • UPMC Hillman Cancer Center ( Site 1014)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • University of California San Francisco ( Site 1044)

    RECRUITING

    San Francisco, California, 94158, United States

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)

    RECRUITING

    Orange, California, 92868, United States

  • University of Chicago Medical Center ( Site 1037)

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.